Cargando…
Autoimmmune hepatitis
Autoimmune hepatitis (AIH) is a T-cell mediated, inflammatory liver disease affecting all ages and characterized by female preponderance, elevated serum transaminase and immunoglobulin G levels, positive circulating autoantibodies, and presence of interface hepatitis at liver histology. AIH type 1,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475398/ https://www.ncbi.nlm.nih.gov/pubmed/34580437 http://dx.doi.org/10.1038/s41423-021-00768-8 |
_version_ | 1784575416999084032 |
---|---|
author | Terziroli Beretta-Piccoli, Benedetta Mieli-Vergani, Giorgina Vergani, Diego |
author_facet | Terziroli Beretta-Piccoli, Benedetta Mieli-Vergani, Giorgina Vergani, Diego |
author_sort | Terziroli Beretta-Piccoli, Benedetta |
collection | PubMed |
description | Autoimmune hepatitis (AIH) is a T-cell mediated, inflammatory liver disease affecting all ages and characterized by female preponderance, elevated serum transaminase and immunoglobulin G levels, positive circulating autoantibodies, and presence of interface hepatitis at liver histology. AIH type 1, affecting both adults and children, is defined by positive anti-nuclear and/or anti-smooth muscle antibodies, while type 2 AIH, affecting mostly children, is defined by positive anti-liver-kidney microsomal type 1 and/or anti-liver cytosol type 1 antibody. While the autoantigens of type 2 AIH are well defined, being the cytochrome P4502D6 (CYP2D6) and the formiminotransferase cyclodeaminase (FTCD), in type 1 AIH they remain to be identified. AIH-1 predisposition is conferred by possession of the MHC class II HLA DRB1*03 at all ages, while DRB1*04 predisposes to late onset disease; AIH-2 is associated with possession of DRB1*07 and DRB1*03. The majority of patients responds well to standard immunosuppressive treatment, based on steroid and azathioprine; second- and third-line drugs should be considered in case of intolerance or insufficient response. This review offers a comprehensive overview of pathophysiological and clinical aspects of AIH. |
format | Online Article Text |
id | pubmed-8475398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84753982021-09-28 Autoimmmune hepatitis Terziroli Beretta-Piccoli, Benedetta Mieli-Vergani, Giorgina Vergani, Diego Cell Mol Immunol Review Article Autoimmune hepatitis (AIH) is a T-cell mediated, inflammatory liver disease affecting all ages and characterized by female preponderance, elevated serum transaminase and immunoglobulin G levels, positive circulating autoantibodies, and presence of interface hepatitis at liver histology. AIH type 1, affecting both adults and children, is defined by positive anti-nuclear and/or anti-smooth muscle antibodies, while type 2 AIH, affecting mostly children, is defined by positive anti-liver-kidney microsomal type 1 and/or anti-liver cytosol type 1 antibody. While the autoantigens of type 2 AIH are well defined, being the cytochrome P4502D6 (CYP2D6) and the formiminotransferase cyclodeaminase (FTCD), in type 1 AIH they remain to be identified. AIH-1 predisposition is conferred by possession of the MHC class II HLA DRB1*03 at all ages, while DRB1*04 predisposes to late onset disease; AIH-2 is associated with possession of DRB1*07 and DRB1*03. The majority of patients responds well to standard immunosuppressive treatment, based on steroid and azathioprine; second- and third-line drugs should be considered in case of intolerance or insufficient response. This review offers a comprehensive overview of pathophysiological and clinical aspects of AIH. Nature Publishing Group UK 2021-09-27 2022-02 /pmc/articles/PMC8475398/ /pubmed/34580437 http://dx.doi.org/10.1038/s41423-021-00768-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Terziroli Beretta-Piccoli, Benedetta Mieli-Vergani, Giorgina Vergani, Diego Autoimmmune hepatitis |
title | Autoimmmune hepatitis |
title_full | Autoimmmune hepatitis |
title_fullStr | Autoimmmune hepatitis |
title_full_unstemmed | Autoimmmune hepatitis |
title_short | Autoimmmune hepatitis |
title_sort | autoimmmune hepatitis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475398/ https://www.ncbi.nlm.nih.gov/pubmed/34580437 http://dx.doi.org/10.1038/s41423-021-00768-8 |
work_keys_str_mv | AT terziroliberettapiccolibenedetta autoimmmunehepatitis AT mieliverganigiorgina autoimmmunehepatitis AT verganidiego autoimmmunehepatitis |